Premalignant  ||| S:0 E:13 ||| JJ
conditions  ||| S:13 E:24 ||| NNS
of  ||| S:24 E:27 ||| IN
the  ||| S:27 E:31 ||| DT
esophagus  ||| S:31 E:41 ||| JJ
Esophageal  ||| S:41 E:52 ||| JJ
cancer  ||| S:52 E:59 ||| NN
has  ||| S:59 E:63 ||| VBZ
often  ||| S:63 E:69 ||| RB
poor  ||| S:69 E:74 ||| JJ
survival  ||| S:74 E:83 ||| NN
when  ||| S:83 E:88 ||| WRB
it  ||| S:88 E:91 ||| PRP
is  ||| S:91 E:94 ||| VBZ
diagnosed  ||| S:94 E:104 ||| VBN
at  ||| S:104 E:107 ||| IN
the  ||| S:107 E:111 ||| DT
time  ||| S:111 E:116 ||| NN
of  ||| S:116 E:119 ||| IN
clinical  ||| S:119 E:128 ||| JJ
symptoms ||| S:128 E:136 ||| NNS
.  ||| S:136 E:138 ||| .
Precancerous  ||| S:138 E:151 ||| JJ
lesions  ||| S:151 E:159 ||| NNS
of  ||| S:159 E:162 ||| IN
the  ||| S:162 E:166 ||| DT
esophagus  ||| S:166 E:176 ||| NNS
are  ||| S:176 E:180 ||| VBP
targets  ||| S:180 E:188 ||| NNS
of  ||| S:188 E:191 ||| IN
interest  ||| S:191 E:200 ||| NN
in  ||| S:200 E:203 ||| IN
selected  ||| S:203 E:212 ||| JJ
group  ||| S:212 E:218 ||| NN
of  ||| S:218 E:221 ||| IN
patients  ||| S:221 E:230 ||| NNS
with  ||| S:230 E:235 ||| IN
important  ||| S:235 E:245 ||| JJ
risk  ||| S:245 E:250 ||| NN
factors ||| S:250 E:257 ||| NNS
.  ||| S:257 E:259 ||| .
Barrett ||| S:259 E:266 ||| NNP
's  ||| S:266 E:269 ||| POS
esophagus  ||| S:269 E:279 ||| FW
-â€Š  ||| S:279 E:282 ||| FW
intestinal  ||| S:282 E:293 ||| FW
metaplasia  ||| S:293 E:304 ||| FW
is  ||| S:304 E:307 ||| VBZ
the  ||| S:307 E:311 ||| DT
main  ||| S:311 E:316 ||| JJ
precursor  ||| S:316 E:326 ||| JJ
lesion  ||| S:326 E:333 ||| NN
for  ||| S:333 E:337 ||| IN
the  ||| S:337 E:341 ||| DT
development  ||| S:341 E:353 ||| NN
of  ||| S:353 E:356 ||| IN
esophageal  ||| S:356 E:367 ||| JJ
adenocarcinoma ||| S:367 E:381 ||| NN
,  ||| S:381 E:383 ||| ,
the  ||| S:383 E:387 ||| DT
tumor  ||| S:387 E:393 ||| NN
with  ||| S:393 E:398 ||| IN
increased  ||| S:398 E:408 ||| JJ
incidence ||| S:408 E:417 ||| NN
.  ||| S:417 E:419 ||| .
The  ||| S:419 E:423 ||| DT
major  ||| S:423 E:429 ||| JJ
risk  ||| S:429 E:434 ||| NN
factor  ||| S:434 E:441 ||| NN
for  ||| S:441 E:445 ||| IN
Barrett ||| S:445 E:452 ||| NNP
's  ||| S:452 E:455 ||| POS
esophagus  ||| S:455 E:465 ||| NN
is  ||| S:465 E:468 ||| VBZ
longterm  ||| S:468 E:477 ||| JJ
gastroesophageal  ||| S:477 E:494 ||| JJ
reflux  ||| S:494 E:501 ||| JJ
disease ||| S:501 E:508 ||| NN
.  ||| S:508 E:510 ||| .
In  ||| S:510 E:513 ||| IN
addition  ||| S:513 E:522 ||| NN
to  ||| S:522 E:525 ||| TO
antireflux  ||| S:525 E:536 ||| VB
therapy ||| S:536 E:543 ||| NN
,  ||| S:543 E:545 ||| ,
the  ||| S:545 E:549 ||| DT
endoscopic  ||| S:549 E:560 ||| JJ
surveillance  ||| S:560 E:573 ||| NN
and  ||| S:573 E:577 ||| CC
followup  ||| S:577 E:586 ||| NNS
are  ||| S:586 E:590 ||| VBP
scheduled  ||| S:590 E:600 ||| VBN
in  ||| S:600 E:603 ||| IN
order  ||| S:603 E:609 ||| NN
to  ||| S:609 E:612 ||| TO
detect  ||| S:612 E:619 ||| VB
adenocarcinoma  ||| S:619 E:634 ||| NNS
and  ||| S:634 E:638 ||| CC
its  ||| S:638 E:642 ||| PRP$
precursor  ||| S:642 E:652 ||| JJ
dysplastic  ||| S:652 E:663 ||| JJ
lesions  ||| S:663 E:671 ||| NNS
at  ||| S:671 E:674 ||| IN
an  ||| S:674 E:677 ||| DT
early  ||| S:677 E:683 ||| JJ
and  ||| S:683 E:687 ||| CC
curable  ||| S:687 E:695 ||| JJ
stage ||| S:695 E:700 ||| NN
.  ||| S:700 E:702 ||| .
The  ||| S:702 E:706 ||| DT
patients  ||| S:706 E:715 ||| NNS
with  ||| S:715 E:720 ||| IN
achalasia ||| S:720 E:729 ||| NN
,  ||| S:729 E:731 ||| ,
caustic  ||| S:731 E:739 ||| JJ
injury  ||| S:739 E:746 ||| NN
of  ||| S:746 E:749 ||| IN
the  ||| S:749 E:753 ||| DT
esophagus  ||| S:753 E:763 ||| NN
and  ||| S:763 E:767 ||| CC
those  ||| S:767 E:773 ||| DT
with  ||| S:773 E:778 ||| IN
head  ||| S:778 E:783 ||| NN
and  ||| S:783 E:787 ||| CC
neck  ||| S:787 E:792 ||| NN
cancer  ||| S:792 E:799 ||| NN
are  ||| S:799 E:803 ||| VBP
at  ||| S:803 E:806 ||| IN
increased  ||| S:806 E:816 ||| JJ
risk  ||| S:816 E:821 ||| NN
of  ||| S:821 E:824 ||| IN
development  ||| S:824 E:836 ||| NN
of  ||| S:836 E:839 ||| IN
the  ||| S:839 E:843 ||| DT
squamous  ||| S:843 E:852 ||| JJ
cell  ||| S:852 E:857 ||| NN
esophageal  ||| S:857 E:868 ||| NN
cancer ||| S:868 E:874 ||| NN
.  ||| S:874 E:876 ||| .
The  ||| S:876 E:880 ||| DT
aim  ||| S:880 E:884 ||| NN
of  ||| S:884 E:887 ||| IN
this  ||| S:887 E:892 ||| DT
paper  ||| S:892 E:898 ||| NN
is  ||| S:898 E:901 ||| VBZ
to  ||| S:901 E:904 ||| TO
provide  ||| S:904 E:912 ||| VB
an  ||| S:912 E:915 ||| DT
overview  ||| S:915 E:924 ||| NN
of  ||| S:924 E:927 ||| IN
the  ||| S:927 E:931 ||| DT
risk  ||| S:931 E:936 ||| NN
factors ||| S:936 E:943 ||| NNS
,  ||| S:943 E:945 ||| ,
epidemiology ||| S:945 E:957 ||| NN
,  ||| S:957 E:959 ||| ,
screening  ||| S:959 E:969 ||| VBG
and  ||| S:969 E:973 ||| CC
surveillance  ||| S:973 E:986 ||| NN
of  ||| S:986 E:989 ||| IN
premalignant  ||| S:989 E:1002 ||| JJ
lesions  ||| S:1002 E:1010 ||| NNS
of  ||| S:1010 E:1013 ||| IN
the  ||| S:1013 E:1017 ||| DT
esophagus ||| S:1017 E:1026 ||| NN
.  ||| S:1026 E:1028 ||| .
Recent  ||| S:1028 E:1035 ||| JJ
endoscopic  ||| S:1035 E:1046 ||| NN
and  ||| S:1046 E:1050 ||| CC
surgical  ||| S:1050 E:1059 ||| JJ
procedures  ||| S:1059 E:1070 ||| NNS
to  ||| S:1070 E:1073 ||| TO
treat  ||| S:1073 E:1079 ||| VB
advanced  ||| S:1079 E:1088 ||| VBN
dysplastic  ||| S:1088 E:1099 ||| JJ
lesions  ||| S:1099 E:1107 ||| NNS
and  ||| S:1107 E:1111 ||| CC
early  ||| S:1111 E:1117 ||| JJ
cancer  ||| S:1117 E:1124 ||| NN
are  ||| S:1124 E:1128 ||| VBP
discussed ||| S:1128 E:1137 ||| VBN
.  ||| S:1137 E:1139 ||| .
